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The present study evaluated the effecti veness of a treatment that combined techniques 
from C ogniti ve- Behav iour Therapy (CBT) and Acceptance and Commitment Therapy 
(ACT ) to all ev iate the psychological di stress and symptom severit y resultant fro m 
psychoti c-type di sorders . Thi s treatment (EVoLVE Therapy; an acron ym fo r Ex pos ing 
Virtues of Li vi ng Valued Existences) was des igned to primaril y ta rget the psycho logical 
d istress assoc iated w ith psychotic di sorde rs and secondaril y to fac ilitate improve ment in 
psychoti c-t ype symptoms. Parti c ipants in thi s study were selected based o n prev ious 
di agnoses o f schi zophreni a, schizoaffec ti ve, and other psyc hi atri c di sorde rs w ith 
psychoti c fea tures. Seven parti cipant s, who had each been lo ng- te rm consumers of 
menta l health services , completed 10 weeks of therapy. Post-graduate students, 1n 
training to become pro fessional psycho log ists, de li ve red supervised the rap y usmg a 
struc tured treatment manual written by the researc her. Pre- treatment , post-treatment and 
5-week fo ll ow-up data were collec ted , using a variety of measures to assess the 
effecti veness of treatme nt. Results we re quite pos iti ve ove rall , w ith some c lients making 
cons iderable improvements in a number of do main s. All 7 partic ipants showed a 
decrease in symptom severity afte r treatment. In additi o n, 6 out o f the 7 parti c ipants 
repo rted an improved quality of li fe fo llowing treatment. M arked improvement 111 
negati ve affect was also ev ident , with a s li ght improve ment in pos itive affect noted . 
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